ArticleScientific reports2025
Constructing a tumor immune microenvironment-driven prognostic model in acute myeloid leukemia using bioinformatics and validation data.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sodium Overload-Related Molecular Subtypes and a Four-Gene Prognostic Signature Predict Survival, Immune Landscape, and Therapeutic Response in Acute Myeloid Leukemia.Molecular carcinogenesis · 2026Article
- Machine learning-driven M2 macrophage signature for precision prediction of survival and therapy response in acute myeloid leukemia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor immune microenvironment (TIME) is a critical determinant of prognosis in acute myeloid leukemia (AML). This study aimed to develop a prognostic model based on immune-related hub differentially expressed genes (hub-DEGs) to refine risk stratification and identify therapeutic targets. Transcriptomic and clinical data from 149 TCGA-AML patients were analyzed using ESTIMATE and xCell algorithms to infer immune scores. Differentially expressed genes (DEGs) between high/low immune score groups were identified, followed by functional enrichment, protein-protein interaction (PPI) network analysis for selecting the hub-DEGs with the highest degree scores, and univariate Cox regression to pinpoint prognostic genes. External validation was performed on 562 GEO-AML patients. The final genes were selected by intersecting the prognostic DEGs and hub-DEGs. Next the immune prognostic model (IPM) was created using these genes. xCell and CIBERSORT algorithm were used to assess the correlation of IPM and different immune cells. Finally, Experimental validation of key genes (CD163, MRC1) was conducted via RT-PCR in 40 AML and 10 control samples. Immune scores correlated with FAB classification (ESTIMATE: p-value = 1.4e - 8; xCell: p-value = 3.7e - 9) and overall survival (ESTIMATE: v = 0.041). Analysis identified 680 immune-related DEGs enriched in immune response pathways. Intersection of prognostic DEGs (n = 34) and hub-DEGs (n = 30) yielded four genes (CD163, IL10, MRC1, FCGR2B). A risk score model stratified patients into high/low-risk groups with divergent survival (p-value = 0.00072). ROC analysis demonstrated predictive accuracy (AUC: 63.38-68.5% for 1-5-year survival). TIME analysis revealed associations between high-risk scores and immunosuppressive cell subsets, including Tregs and M2 macrophages. RT-qPCR confirmed elevated CD163 in AML (p < 0.001), while MRC1 showed no differential expression. This study establishes a TIME-centric prognostic model with clinical utility for risk stratification and therapeutic targeting in AML. Prospective validation and integration of advanced genomic technologies are warranted to refine its translational applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.